-3.74% $77.39
America/New_York / 16 mai 2024 @ 13:06
Live Signal Biomarin Pharmaceutical Inc
Buy @ $79.81
Issued: 16 mai 2024 @ 09:34 / Return: -3.03%
Previous Signal: sell @ 15 mai 2024 @ 15:41 - Return: -0.88 %
$1 invested is now $1.08 or 7.65 % *
(* In 14 weeks 2 days 2 hours 36 minutes and 31 seconds .)
Dividend: X | Profitable: Y | Good Trading Volume: Y
About Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Last live signals for Biomarin Pharmaceutical
The Live signals presented on this page help you to determine when to buy or sell Biomarin Pharmaceutical. The signals has upwards to 1 minute delay and like all signals there is an given chance for error or mistakes. The signals are not definite and stockinvestor.us hold no responsibility for any action taken upon these signals as clearly described in the TOS. The signals is based on technical analysis based on a wide range of indicators.
Right now there is a buy signal in the stock from the rsi14 signal,and we believe current price holds an opportunity to make profit.
Answer last updated: 16 mai 2024 @ 13:06
We cannot find any recorded dividends paid in our systems.
Yes, the consensus target for Biomarin Pharmaceutical Inc is $115.25, which is $37.86, or 48.92 % above today's price. The analysts has low target of $85.00 and a high target of $135.00
We cannot find data for Biomarin Pharmaceutical 10 years ago, but if you had invested on Friday 17th of May 2019 when price was $88.71 you would have made a loss of $0 per share or -12.72 %
Yes, the average daily trading liquidity for Biomarin Pharmaceutical is $1 560 696 . You should therefore be able to get in and out of your positions relatively fast.
Biomarin Pharmaceutical has a normal ratio of the business financed by loans. This put the company at some risk in periods of high inflation where cost of borrowing money usually go up. With a normal cash flow to debt ratio of 0.26 the company's ability to pay of the debt is normal. Biomarin Pharmaceutical has a good net profit margin of 8.30% and should have high tolerances against inflation as the profit margin can be reduced to maintain market positions and overall sales.
We have calculated the inflation risk for Biomarin Pharmaceutical to be low [0.4 of 1]
US inflation for March 2024 was 0.38%. Over last 12 months the US inflation is 3.48%. The 10 year treasury yield that indicate the future interest level is currently 4.36 and is up 0.47 over last 30 days.